HC Wainwright Reaffirms Buy Rating for UroGen Pharma (NASDAQ:URGN)
HC Wainwright reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a research note published on Monday morning,Benzinga reports. They currently have a $55.00 target price on the stock. A number of other analysts also recently weighed in on the stock. Scotiabank started coverage on shares of UroGen Pharma in […]
HC Wainwright reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a research note published on Monday morning,Benzinga reports. They currently have a $55.00 target price on the stock. A number of other analysts also recently weighed in on the stock. Scotiabank started coverage on shares of UroGen Pharma in […]
